---
title: Descriptive Study of Psychiatric Symptoms in White-Sutton Syndrome
nct_id: NCT07380594
overall_status: RECRUITING
sponsor: Centre Hospitalier Universitaire Dijon
study_type: OBSERVATIONAL
primary_condition: People With White Sutton Syndrome
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07380594.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07380594"
ct_last_update_post_date: 2026-02-02
last_seen_at: "2026-05-12T06:22:07.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Descriptive Study of Psychiatric Symptoms in White-Sutton Syndrome

**NCT ID:** [NCT07380594](https://clinicaltrials.gov/study/NCT07380594)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Centre Hospitalier Universitaire Dijon
- **Conditions:** People With White Sutton Syndrome
- **Start Date:** 2026-01
- **Completion Date:** 2028-01
- **CT.gov Last Update:** 2026-02-02

## Brief Summary

White Sutton syndrome is a rare developmental disorder identified following the description of de novo variations in the POGZ gene, responsible for neurocognitive disorders that may be associated with other signs including hypotonia, deafness, visual disorders, tendency to be overweight, gastrointestinal disorders, convulsions, sleep disorders with sleep apnoea and facial morphological peculiarities. A descriptive study focusing on the neuropsychological assessments of patients showed an absence of systematic intellectual disability and clinical heterogeneity. Psychiatrically, anxiety seems to predominate and manifest itself broadly in the form of generalised anxiety disorder, phobic disorder or obsessive-compulsive disorder. Some patients may also present with autism spectrum disorders, behavioural disorders and attention disorders with or without hyperactivity. Psychiatric symptoms appear to be present in many patients, but with varying frequency and heterogeneous manifestations. Psychiatric manifestations and symptoms can complicate the already complex and often multidisciplinary management of patients. It is therefore essential to define more precisely the psychological characteristics of patients and the psychiatric comorbidities that may be associated with this condition in order to adapt behavioural, environmental and therapeutic management strategies.Psychiatric symptoms appear to be present in many patients, but with varying frequency and heterogeneous manifestations. Psychiatric manifestations and symptoms can complicate the already complex and often multidisciplinary management of patients. It is therefore essential to define more precisely the psychological characteristics of patients and the psychiatric comorbidities that may be associated with this condition in order to adapt behavioural, environmental and therapeutic management strategies. This would make it possible to consider methods for early detection and faster management of psychiatric comorbidities.

## Eligibility

- **Minimum age:** 6 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Individuals with White Sutton syndrome (genetic mutation identified by genetic testing) adults and children, and French speakers
* Patient or carer able to complete a questionnaire in French lasting 1 to 2 hours
* Age \> 6 years (lower age limit for the primary endpoint)
* Consent of the patient (and their parents if the patient is a minor) and legal representative (for patients under guardianship or trusteeship) to participate in the study

Exclusion Criteria:

* Absence of genetic confirmation of the diagnosis
* Refusal by parents or legal representatives to participate or authorise the use of data for research purposes
* Technical impossibility of conducting the interview by videoconference or telephone
* Unfeasible protocol
* patient interruption
```

## Arms

- **People with White Sutton syndrome**

## Interventions

- **Interviews** (OTHER) — An inclusion interview and a second interview 3 to 6 months after the inclusion interview
- **Questionnaires** (OTHER) — K-SADS-PL DSM5 et M.I.N.I 5.0.0 French version / DSM-IV

## Primary Outcomes

- **Assessment of symptoms and psychiatric diagnoses through a medical interview.** _(time frame: 6 to 9 months)_
- **Assessment of symptoms and psychiatric diagnoses through an MINI scales for adults.** _(time frame: 6 to 9 months)_
- **Assessment of symptoms and psychiatric diagnoses through a K-SADS scales for children aged 6 to 18.** _(time frame: 6 to 9 months)_

## Locations (1)

- CHU Dijon Bourgogne, Dijon, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu dijon bourgogne|dijon||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07380594.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07380594*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*